PRECIGEN, INC. Other Significant Noncash Transaction, Value of Consideration Received
PRECIGEN, INC. (PGEN) reported Other Significant Noncash Transaction, Value of Consideration Received of $0 for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationReceived1 · last filed 2016-11-09
- PRECIGEN, INC. other significant noncash transaction, value of consideration received for the quarter ending 2016-09-30 was $0.00.
- PRECIGEN, INC. other significant noncash transaction, value of consideration received for the quarter ending 2015-09-30 was $0.00, a 100.00% decline year-over-year.
- PRECIGEN, INC. other significant noncash transaction, value of consideration received for the quarter ending 2014-09-30 was $10.00M.
| Period end | Other Significant Noncash Transaction, Value of Consideration Received 3 month | Other Significant Noncash Transaction, Value of Consideration Received 6 month | Other Significant Noncash Transaction, Value of Consideration Received 9 month |
|---|---|---|---|
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $0.00 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $0.00 10-Q · filed 2016-08-09 | ||
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $5.00M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $5.00M 10-Q · filed 2016-08-09 | ||
| 2014-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $10.00M 10-Q · filed 2015-11-09 | |
| 2014-06-30 | $0.00 10-Q · filed 2015-08-10 | ||
| 2013-09-30 | $0.00 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |